Press Release January 12, 2006

Supernus Pharmaceuticals Secures $27.5 Million in Initial Funding

BOSTON, Jan. 12, 2006 — Supernus Pharmaceuticals has announced that it has secured $27.5 million in an initial round of funding from New Enterprise Associates (NEA) and OrbiMed Advisors LLC to spin off the product formulation and development business of Shire Laboratories Inc. and to fund buildup of a portfolio of drug candidates. Baltimore-based NEA contributed $17.5 million, and OrbiMed of New York contributed $10 million.

Mitchell Bloom, partner at Goodwin Procter, represented the investors in this transaction.